# XBiotech Inc. (XBIT)

Source: https://www.quantisnow.com/company/XBIT
Generated: 2026-11-17T04:12:32.307Z

- Ticker: XBIT
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- SEC CIK: 0001626878
- Website: xbiotech.com

## About

XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of antibody therapies for treating oncology, inflammatory conditions, and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and True Human COVID-19 therapy for treating the COVID-19 mutant virus. In addition, the company provides clinical trial contract research operations to conduct two large, double-blind placebo-controlled Phase II clinical studies. The company was incorporated in 2005 and is headquartered in Austin, Texas.

## Latest XBIT news and filings

- 2026-11-13 20:49 UTC [Insider Buy] [Director Simard John bought $143,409 worth of shares (70,000 units at $2.05), increasing direct ownership by 2% to 4,261,690 units (SEC Form 4)](https://www.quantisnow.com/insight/director-simard-john-bought-143409-worth-of-shares-70000-units-6790312)
- 2026-11-12 15:53 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6787116)
- 2026-10-28 19:32 UTC [SEC Form 4] [SEC Form 4 filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-xbiotech-inc-6761084)
- 2026-10-28 19:30 UTC [SEC Form 3] [SEC Form 3 filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-3-filed-by-xbiotech-inc-6761082)
- 2026-10-28 18:37 UTC [Insider Buy] [Director Simard John bought $711,251 worth of shares (368,524 units at $1.93) (SEC Form 4)](https://www.quantisnow.com/insight/director-simard-john-bought-711251-worth-of-shares-368524-units-6761052)
- 2026-10-26 13:39 UTC [SEC Form 8-K] [SEC Form 8-K filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-xbiotech-inc-6757306)
- 2026-10-23 13:17 UTC [XBiotech Announces Election of Sushma Shivaswamy and Jan-Paul Simard as Co-Chief Executive Officers](https://www.quantisnow.com/insight/xbiotech-announces-election-of-sushma-shivaswamy-and-jan-paul-simard-as-6756009)
- 2026-10-19 13:00 UTC [XBiotech Announces Positive Phase II Final Efficacy Results from Investigator-Sponsored TASKIN Trial in Refractory Metastatic Colorectal Cancer](https://www.quantisnow.com/insight/xbiotech-announces-positive-phase-ii-final-efficacy-results-from-investigator-sponsored-6750195)
- 2026-10-02 15:13 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-xbiotech-inc-6733847)
- 2026-08-13 15:26 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6679815)
- 2026-06-15 13:00 UTC [XBiotech Launches Phase II Clinical Trial Evaluating Vilamakitug for the Treatment of Active Axial Spondyloarthritis](https://www.quantisnow.com/insight/xbiotech-launches-phase-ii-clinical-trial-evaluating-vilamakitug-for-the-6602068)
- 2026-05-14 18:43 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6553367)
- 2026-04-29 17:02 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by XBiotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-xbiotech-inc-6520721)
- 2026-03-13 18:33 UTC [SEC Form 10-K] [SEC Form 10-K filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-xbiotech-inc-6446687)
- 2026-03-11 21:09 UTC [SEC Form S-8] [SEC Form S-8 filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-s-8-filed-by-xbiotech-inc-6442570)
- 2026-01-23 21:33 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xbiotech-inc-6359397)
- 2025-12-09 14:00 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-leadership-update-6308300)
- 2025-11-12 16:45 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6273687)
- 2025-11-12 14:56 UTC [SEC Form 4] [SEC Form 4 filed by Director Rademaker Craig Evan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-rademaker-craig-evan-6273560)
- 2025-11-12 14:54 UTC [SEC Form 4] [SEC Form 4 filed by Director Soffer David Spencer](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-soffer-david-spencer-6273559)
- 2025-11-12 14:53 UTC [SEC Form 4] [SEC Form 4 filed by Director Kuendig Thomas Martin](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-kuendig-thomas-martin-6273556)
- 2025-11-12 14:51 UTC [SEC Form 4] [SEC Form 4 filed by Director Troy Tevi David](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-troy-tevi-david-6273551)
- 2025-10-15 16:54 UTC [SEC Form 8-K] [Amendment: XBiotech Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/amendment-xbiotech-inc-filed-sec-form-8-k-leadership-update-6233795)
- 2025-10-03 15:15 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-entry-into-a-material-6221972)
- 2025-09-30 14:20 UTC [SEC Form 3] [SEC Form 3 filed by new insider Soffer David Spencer](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-soffer-david-spencer-6215710)
- 2025-09-30 13:21 UTC [SEC Form 3] [New insider Kuendig Thomas Martin claimed ownership of 300,000 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-kuendig-thomas-martin-claimed-ownership-of-300000-shares-6215648)
- 2025-09-29 14:53 UTC [SEC Form 3] [SEC Form 3 filed by new insider Troy Tevi David](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-troy-tevi-david-6214180)
- 2025-09-16 16:17 UTC [SEC Form 3] [New insider Rademaker Craig Evan claimed ownership of 170,985 shares (SEC Form 3)](https://www.quantisnow.com/insight/new-insider-rademaker-craig-evan-claimed-ownership-of-170985-shares-6202215)
- 2025-09-02 17:10 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-submission-of-matters-to-6185507)
- 2025-08-13 18:49 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6162739)
- 2025-07-07 21:23 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-xbiotech-inc-6113070)
- 2025-06-24 21:06 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-leadership-update-6097692)
- 2025-05-14 19:55 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-xbiotech-inc-6038550)
- 2025-04-29 19:59 UTC [SEC Form 10-K] [Amendment: SEC Form 10-K/A filed by XBiotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-10-ka-filed-by-xbiotech-inc-6006938)
- 2025-04-07 20:50 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-notice-of-delisting-or-5979988)
- 2025-03-31 22:43 UTC [SEC Form 8-K] [XBiotech Inc. filed SEC Form 8-K: Leadership Update](https://www.quantisnow.com/insight/xbiotech-inc-filed-sec-form-8-k-leadership-update-5968179)
- 2025-03-19 19:03 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Simard John](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-simard-john-5952071)
- 2025-03-18 19:36 UTC [SEC Form 10-K] [SEC Form 10-K filed by XBiotech Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-xbiotech-inc-5949343)
- 2025-02-04 21:53 UTC [SEC Form 4] [SEC Form 4 filed by Chief Executive Officer Simard John](https://www.quantisnow.com/insight/sec-form-4-filed-by-chief-executive-officer-simard-john-5870616)
- 2025-01-27 19:39 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by XBiotech Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-xbiotech-inc-5857945)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/XBIT
- Earnings history: https://www.quantisnow.com/earnings/XBIT
- Dividend history: https://www.quantisnow.com/dividends/XBIT
- Insider transactions: https://www.quantisnow.com/insiders/XBIT
- Options chain: https://www.quantisnow.com/options/XBIT
- SEC 8-K filings only: https://www.quantisnow.com/company/XBIT/8-k
- RSS and alerts for XBIT: https://www.quantisnow.com/docs/rss-feeds.md
